[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633371":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":30,"responsibleParty":47,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Pirtobrutinib Treatment Cohort",null,"Patients with cBTKi-resistant\u002Fintolerant mature B-cell lymphoma receiving pirtobrutinib 200 mg once daily in real-world clinical practice.Receive pitobrutinib as monotherapy or in combination, with a recommended dose of 200 mg once daily until disease progression or unacceptable toxicity occurs.",[13],"Drug: Pirtobrutinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Pirtobrutinib","Pirtobrutinib 200 mg administered orally once daily, in accordance with standard clinical practice, until disease progression, unacceptable toxicity, or study completion.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Ou BAI, MD, PhD","CONTACT","+86-13039046656","oubai16@163.com",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Jia Li, MD","+86 13844898514","lijia0810@jlu.edu.cn",[31],{"facility":32,"status":10,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"The First Bethune Hospital of Jilin University","Changchun","Jilin","130021","China","CN",{"type":39,"coordinates":40},"Point",[41,42],125.32278,43.88,{"lat":42,"lon":41},[45,46],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Ou Bai, MD\u002FPHD","Principal Investigator, Professor","100633371","a-real-world-study-of-pirtobrutinib-in-cbtki-resistantintolerant-mature-b-cell-lymphoma-100633371",false,"NCT07525817","A Real-World Study of Pirtobrutinib in cBTKi-Resistant\u002FIntolerant Mature B-Cell Lymphoma","A Prospective, Multicenter, Real-World Study of Pirtobrutinib in Patients With Mature B-Cell Lymphoma Resistant or Intolerant to Covalent Bruton Tyrosine Kinase Inhibitors","Inclusion Criteria:\n\n* Age ≥18 years;\n* Histopathological confirmation of mature B-cell lymphoma, primarily including CLL\u002FSLL, MCL, FL, MZL, WM\u002FLPL, etc.;\n* Disease progression and\u002For intolerance after prior treatment with ≥1 cBTKi (including ibrutinib, ibrutinib, zanubrutinib, or acitinib);\n* ECOG PS 0-2;\n* Adequate liver and kidney function: the following criteria must be met simultaneously: 1) AST and ALT ≤ 3×ULN; 2) Total bilirubin ≤ 1.5×ULN; 3) Creatinine clearance rate ≥ 30 mL\u002Fmin;\n* Participants must be voluntary and capable of completing the study procedures and follow-up examinations;\n* Informed consent must be obtained voluntarily prior to screening.\n\nExclusion Criteria:\n\n* Patients with known allergic reactions to any component or excipient of piteutinib;\n* Patients concurrently participating in other clinical studies;\n* A history of clinically significant, uncontrolled cardiac,\n* Cardiovascular disease, or myocardial infarction within 6 months prior to planned initiation of piteutinib therapy;\n* Uncontrolled systemic bacterial, viral, fungal, or parasitic infections; current use of potent CYP3A4 inhibitors or inducers and\u002For potent P-gp inhibitors;\n* Positive human immunodeficiency virus (HIV) testing;\n* Active hepatitis B or C: 1) Patients with positive hepatitis B virus (HBV) DNA testing and controlled disease status may be enrolled with investigator approval. For HBV DNA-positive patients, concurrent antiviral therapy is required. 2) Patients with prior hepatitis C virus (HCV) infection history who have completed antiviral therapy with viral loads below the quantitative limit may be enrolled;\n* Based on the investigator's assessment, participants may be unable to complete all study protocol requirements, including follow-up visits, and\u002For adhere to all study procedures;\n* A history of other clinically significant diseases or comorbidities; and any safety risks or potential interference with study completion as evaluated by investigators.","ALL","18 Years",{"count":61,"type":62},40,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, real-world study to evaluate the efficacy and safety of pirtobrutinib in patients with mature B-cell lymphoma who are resistant or intolerant to prior covalent BTK inhibitors. The primary endpoint is overall response rate (ORR). Secondary endpoints include best overall response (BOR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. A total of 40 patients will be enrolled across 8 centers in China.",[66],"Mature B-Cell Lymphoma",[17,68,69],"Covalent BTK inhibitor","Mature B-cell lymphoma","NOT_YET_RECRUITING","2026-04-07",{"date":73,"type":74},"2026-04-13","ACTUAL",{"date":76,"type":62},"2026-04-01",{"date":78,"type":62},"2028-12-31",{"name":49,"class":6},1]